P53 and Cancer-Associated Sialylated Glycans Are Surrogate Markers of Cancerization of the Bladder Associated with Schistosoma haematobium Infection

• Júlio Santos ,

  Contributed equally to this work with: Júlio Santos, Elisabete Fernandes, José Alexandre Ferreira, Lúcio L. Santos

  Affiliations Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal, Clínica Sagrada Esperança, Luanda, Angola

  ⨯
• Elisabete Fernandes ,

  Contributed equally to this work with: Júlio Santos, Elisabete Fernandes, José Alexandre Ferreira, Lúcio L. Santos

  Affiliations Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal, Grupo de Investigação em Cancro Digestivo (GICD), Porto, Portugal

  ⨯
• José Alexandre Ferreira ,

  Contributed equally to this work with: Júlio Santos, Elisabete Fernandes, José Alexandre Ferreira, Lúcio L. Santos

  * E-mail: alexandrecastroferreira@gmail.com (JAF); llarasantos@gmail.com (LLS)

  Affiliations Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal, Department of Chemistry of the University of Aveiro, Aveiro, Portugal

  ⨯
• Luís Lima,

  Affiliations Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal, Research Department, LPCC-Portuguese League Against Cancer (NRNorte), Porto, Portugal, Núcleo de Investigação em Farmácia – Centro de Investigação em Saúde e Ambiente (CISA), School of Allied Health Sciences – Polytechnic Institute of Porto, Porto, Portugal

  ⨯
• Ana Tavares,

  Affiliations Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal, Department of Pathology, Portuguese Institute for Oncology of Porto, Porto, Portugal

  ⨯
• Andreia Peixoto,

  Affiliation Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal

  ⨯
• Beatriz Parreira,

  Affiliation Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal

  ⨯
• José Manuel Correia da Costa,

  Affiliations Center for the Study of Animal Science (ICETA), University of Porto, Porto, Portugal, INSA, National Institute of Health, Porto, Portugal

  ⨯
• Paul J. Brindley,

  Affiliation Research Center for Neglected Diseases of Poverty- Department of Microbiology, Immunology & Tropical Medicine, School of Medicine & Health Sciences, George Washington University, Washington, D.C., United States of America

  ⨯
• Carlos Lopes,

  Affiliations Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal, Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal

  ⨯
• Lúcio L. Santos

  Contributed equally to this work with: Júlio Santos, Elisabete Fernandes, José Alexandre Ferreira, Lúcio L. Santos

  * E-mail: alexandrecastroferreira@gmail.com (JAF); llarasantos@gmail.com (LLS)

  Affiliations Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal, Health School of University of Fernando Pessoa, Porto, Portugal, Department of Surgical Oncology, Portuguese Institute for Oncology, Porto, Portugal, National Cancer Center, Luanda, Angol

  ⨯